Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 1,799 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,799 shares of the business’s stock in a transaction on Friday, May 16th. The stock was sold at an average price of $67.53, for a total transaction of $121,486.47. Following the completion of the sale, the insider now owns 84,797 shares in the company, valued at $5,726,341.41. This represents a 2.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, May 15th, Martina M.D. Flammer sold 9,925 shares of Insmed stock. The shares were sold at an average price of $65.47, for a total transaction of $649,789.75.
• On Wednesday, May 14th, Martina M.D. Flammer sold 1,744 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $114,423.84.
• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total value of $570,146.48.

Insmed Price Performance

Shares of INSM opened at $68.51 on Wednesday. The stock’s 50 day moving average is $71.32 and its two-hundred day moving average is $73.13. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $12.48 billion, a PE ratio of -12.26 and a beta of 0.84. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million for the quarter, compared to analysts’ expectations of $91.63 million. During the same quarter in the previous year, the firm posted ($1.06) earnings per share. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. Research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cullen Frost Bankers Inc. grew its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 221 shares during the period. Elequin Capital LP bought a new position in Insmed during the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Finally, Spire Wealth Management bought a new stake in shares of Insmed in the 4th quarter valued at approximately $47,000.

Analysts Set New Price Targets

INSM has been the subject of several recent research reports. Wells Fargo & Company boosted their price target on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Bank of America upped their price target on Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. UBS Group lowered their target price on shares of Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research note on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Insmed in a report on Monday, May 12th. Finally, Guggenheim restated a “buy” rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $94.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.